Emre Sedar Saygili, Yasir S Elhassan, Alessandro Prete, Juliane Lippert, Barbara Altieri, Cristina L Ronchi
{"title":"Machine learning-based survival prediction tool for adrenocortical carcinoma.","authors":"Emre Sedar Saygili, Yasir S Elhassan, Alessandro Prete, Juliane Lippert, Barbara Altieri, Cristina L Ronchi","doi":"10.1210/clinem/dgaf096","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy with difficult to predict clinical outcomes. The S-GRAS score combines clinical and histopathological variables (tumour stage, grade, resection status, age, and symptoms) and showed good prognostic performance for patients with ACC.</p><p><strong>Objective: </strong>To improve ACC prognostic classification by applying robust machine learning (ML) models.</p><p><strong>Method: </strong>We developed ML models to enhance outcome prediction using the published S-GRAS dataset (n=942) as the training cohort and an independent dataset (n=152) for validation. Sixteen ML models were constructed based on individual clinical variables. The best performing models were used to develop a web-based tool for individualized risk prediction.</p><p><strong>Results: </strong>Quadratic Discriminant Analysis, Light Gradient Boosting Machine, and AdaBoost Classifier models exhibited the highest performance, predicting 5-year overall mortality (OM), and 1-year, and 3-year disease progression (DP) with F1 scores of 0.79, 0.63, and 0.83 in the training cohort, and 0.72, 0.60, and 0.83 in the validation cohort. Sensitivity and specificity for 5-year OM were at 77% and 77% in the training cohort, and 65% and 81% in the validation cohort, respectively. A web-based tool (https://acc-survival.streamlit.app) was developed for easily applicable and individualized risk prediction of mortality and disease progression.</p><p><strong>Conclusion: </strong>S-GRAS parameters can efficiently predict outcome in patients with ACC, even using a robust ML model approach. Our web app instantly estimates the mortality and disease progression for patients with ACC, representing an accessible tool to drive personalised management decisions in clinical practice.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0000,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Endocrinology & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1210/clinem/dgaf096","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Context: Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy with difficult to predict clinical outcomes. The S-GRAS score combines clinical and histopathological variables (tumour stage, grade, resection status, age, and symptoms) and showed good prognostic performance for patients with ACC.
Objective: To improve ACC prognostic classification by applying robust machine learning (ML) models.
Method: We developed ML models to enhance outcome prediction using the published S-GRAS dataset (n=942) as the training cohort and an independent dataset (n=152) for validation. Sixteen ML models were constructed based on individual clinical variables. The best performing models were used to develop a web-based tool for individualized risk prediction.
Results: Quadratic Discriminant Analysis, Light Gradient Boosting Machine, and AdaBoost Classifier models exhibited the highest performance, predicting 5-year overall mortality (OM), and 1-year, and 3-year disease progression (DP) with F1 scores of 0.79, 0.63, and 0.83 in the training cohort, and 0.72, 0.60, and 0.83 in the validation cohort. Sensitivity and specificity for 5-year OM were at 77% and 77% in the training cohort, and 65% and 81% in the validation cohort, respectively. A web-based tool (https://acc-survival.streamlit.app) was developed for easily applicable and individualized risk prediction of mortality and disease progression.
Conclusion: S-GRAS parameters can efficiently predict outcome in patients with ACC, even using a robust ML model approach. Our web app instantly estimates the mortality and disease progression for patients with ACC, representing an accessible tool to drive personalised management decisions in clinical practice.
期刊介绍:
The Journal of Clinical Endocrinology & Metabolism is the world"s leading peer-reviewed journal for endocrine clinical research and cutting edge clinical practice reviews. Each issue provides the latest in-depth coverage of new developments enhancing our understanding, diagnosis and treatment of endocrine and metabolic disorders. Regular features of special interest to endocrine consultants include clinical trials, clinical reviews, clinical practice guidelines, case seminars, and controversies in clinical endocrinology, as well as original reports of the most important advances in patient-oriented endocrine and metabolic research. According to the latest Thomson Reuters Journal Citation Report, JCE&M articles were cited 64,185 times in 2008.